Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: A multi-institutional collaboration

Clinical Lung Cancer

Volumn 11, Issue 6, 2010, Pages 396-404

  D'Jaen, Gabriela ^a   Pantanowitz, Liron ^b   Bower, Mark ^c   Buskin, Susan ^d,e   Neil, Nancy ^e,f   Greco, Erin ^g   Cooley, Timothy ^h,i   Henry, David ^j   Stem, Jonathan ^j   Dezube, Bruce ^k   Stebbing, Justin ^l   Aboulafia, David ^a,e  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f ICON CLINICAL RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BOSTON MEDICAL CENTER   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Joan Karnell Cancer Center   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l CHARING CROSS HOSPITAL   (United Kingdom)

more..

Author keywords

AIDS; ASD; HAART

Indexed keywords

ATAZANAVIR; CARBOPLATIN; CISPLATIN; EMTRICITABINE; ERLOTINIB; GEMCITABINE; LAMIVUDINE; MITOMYCIN; NAVELBINE; PLATINUM DERIVATIVE; RITONAVIR; TAXANE DERIVATIVE; TENOFOVIR; VINCA ALKALOID;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMPARATIVE STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFICACY; ESOPHAGUS CANDIDIASIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY ASSOCIATED PRIMARY LUNG CANCER; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY FAILURE; LUNG ADENOCARCINOMA; LUNG INSUFFICIENCY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHUMAN; PERIPHERAL NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 78649281568     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.051     Document Type: Article

References (55)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 1999; 48:1-22.
3. Centers for Disease Control and Prevention. Trends in Annual Age-Adjusted Rate of Death due to HIV Disease, USA, 1987-2005. Atlanta: Centers for Disease Control and Prevention. Available at: www.cdc.gov/hiv/topics/surveillance/ resources/slides/mortality/Accessed: June 23, 2009.
4. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397-406.
5. Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-22.
6. Palella FJ, Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
7. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis 2009; 48:633-9.
8. Hooshyar D, Hanson DL, Wolfe M, et al. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS 2007; 21:2093-100.
9. Lavole A, Wislez M, Antoine M, et al. A new challenge in the HIV-infected population. Lung Cancer 2006; 51:1-11.
10. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383-8.
11. Patel P, Hanson DL, Sullivan PS, et al; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-36.
12. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884-90.
13. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-32.
14. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207-13.
15. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infections is associated with an increased risk of lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-10.
16. Brock MV, Hooker CM, Engels EA. Delayed diagnosis and elevated mortality in an urban population with HIV and LC: implications for patient care. J Acquir Immune Defic Syndr 2006; 43:47-55.
17. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 2007; 370:59-67.
18. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-9.
19. Lavolé A, Chouaid C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 2009; 65:345-50.
20. Schneider E, Whitmore S, Glynn MK, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged 18 months to < 13 years\United States 2008. MMWR Recomm Rep 2008;57:(RR10) 1-8.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.
22. Program Limited-Use Data (1973-2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission. Available at: www.seer.cancer. gov. Accessed: May 25, 2010
23. Ries LAG, Young JL, Keel GE, et al. (editors). SEER Survival monograph: Cancer Survival Among Adults: U.S. SEER program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, Bethesda, MD: NIH Pub. No. 07-6215, 2007.
24. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267:1798-805.
25. Barash E, Kahle E, Buskin S. Summary results from the Adult and Adolescent Spectrum of HIV Disease Project. HIV/AIDS Epidemiology Rep, Publisher location: publisher name; 2005:17-23.
26. Kaplan EL, Meier P. Nonparametric estimation from Incomplete Observations. J Am Stat Assoc 1958; 53:457-81.
27. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000; 88:563-9.
28. Sridhar KS, Flores MR, Raub WA, Jr, et al. Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 1992; 102:1704-8.
29. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996;15:325-339.
30. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-8.
31. Stall RD, Greenwood GL, Acree M, et al. Cigarette smoking among gay and bisexual men. Am J Public Health 1999; 89:1875-8.
32. Thompson SC, Nanni C, Levine A. The stressors and stress of being HIV-positive. AIDS Care 1996; 8:5-14.
33. Gordon SB, Janoff EN, Sloper D, et al. HIV-1 infection is associated with altered innate pulmonary immunity. J Infect Dis 2005; 192:1412-6.
34. Agostini C, Sancetta R, Cerutti A, et al. Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. J Leukoc Biol 1995; 58:495-500.
35. Allard JP, Aghdassi E, Chau J, et al. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998; 67:143-7.
36. Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989; 2:1294-8.
37. Tong X, Li K, Luo Z, et al. Decreased TIP30 expression promotes tumor metastasis in lung cancer. Am J Pathol 2009; 174:1931-9.
38. Baker ME, Yan L, Pear MR. Three-dimensional model of human TIP30, a coacti-vator for HIV-1 Tat-activated transcription, and CC3, a protein associated with metastasis suppression. Cell Mol Life Sci 2000; 57:851-8.
39. Liang HY, Li XL, Yu XS, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: A systematic review. Int J Cancer 2009; 125:2936-44.
40. Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772-82.
41. Girardi E, Antonucci G, Vanacore P, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24:11-7.
42. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst 1984; 73:383-9.
43. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-45.
44. Parker MS, Leveno DM, Campbell TJ, et al. AIDS-related bronchogenic carcinoma: fact or fiction? Chest 1998; 113:154-61.
45. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-5.
46. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355:479-85.
47. Wistuba II, Behrens C, Milchgrub S, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279:1554-9.
48. Bazoes A, Bower M, Powles T Smoke and mirrors: HIV-related lung cancer. Curr Opin Oncol 2008; 20:529-33.
49. Hakimian R, Fang H, Thomas L, et al. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007; 2:268-72.
50. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-91.
51. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943-6.
52. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT N Engl J Med 2009; 361:32-9.
53. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65:720-5.
54. Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics 2005; 25:1357-68.
55. Bhargava P, Parker JA, Dezube BJ. Pitfalls of diagnosis based on abnormal flow cytometry and [(18)F]fluorodeoxyglucose positron emission tomography. Clin Lymphoma Myeloma 2008; 8:117-20.